[go: up one dir, main page]

WO2005086814A3 - Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3) - Google Patents

Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3) Download PDF

Info

Publication number
WO2005086814A3
WO2005086814A3 PCT/US2005/007586 US2005007586W WO2005086814A3 WO 2005086814 A3 WO2005086814 A3 WO 2005086814A3 US 2005007586 W US2005007586 W US 2005007586W WO 2005086814 A3 WO2005086814 A3 WO 2005086814A3
Authority
WO
WIPO (PCT)
Prior art keywords
gsk
regulation
methods
glycogen synthase
synthase kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/007586
Other languages
French (fr)
Other versions
WO2005086814A2 (en
Inventor
Michael Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Priority to US10/598,671 priority Critical patent/US8048454B2/en
Publication of WO2005086814A2 publication Critical patent/WO2005086814A2/en
Anticipated expiration legal-status Critical
Publication of WO2005086814A3 publication Critical patent/WO2005086814A3/en
Priority to US13/244,165 priority patent/US20120309807A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates generally to a method of treating inflammation and associated diseases and disorders by administering an agent that inhibits glycogen synthase kinase 3 activity.
PCT/US2005/007586 2004-03-09 2005-03-09 Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3) Ceased WO2005086814A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/598,671 US8048454B2 (en) 2004-03-09 2005-03-09 Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (GSK-3)
US13/244,165 US20120309807A1 (en) 2004-03-09 2011-09-23 Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55164604P 2004-03-09 2004-03-09
US60/551,646 2004-03-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/244,165 Division US20120309807A1 (en) 2004-03-09 2011-09-23 Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)

Publications (2)

Publication Number Publication Date
WO2005086814A2 WO2005086814A2 (en) 2005-09-22
WO2005086814A3 true WO2005086814A3 (en) 2006-11-02

Family

ID=34976164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/007586 Ceased WO2005086814A2 (en) 2004-03-09 2005-03-09 Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)

Country Status (2)

Country Link
US (2) US8048454B2 (en)
WO (1) WO2005086814A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086814A2 (en) * 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
ATE542535T1 (en) * 2005-05-04 2012-02-15 Develogen Ag USE OF AZAPAULLONE FOR THE PREVENTION AND TREATMENT OF PANCREATIC AUTOIMMUNE DISEASES
EP1885454A2 (en) * 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
AU2006321287B2 (en) * 2005-12-01 2013-05-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases
WO2008012031A2 (en) * 2006-07-25 2008-01-31 Universität Bern Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9949979B2 (en) * 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
EP3173788A3 (en) * 2012-03-14 2017-07-12 Marx, Stephen Means and methods for diagnostics and therapeutics of diseases
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US20160051514A1 (en) * 2013-05-03 2016-02-25 The Brigham And Women's Hospital, Inc. Methods for treatment of cardiomyopathy
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN114377009A (en) * 2020-10-21 2022-04-22 中国医学科学院药物研究所 Application of SB216763 in preparation of anti-influenza virus medicine
CN117144587A (en) * 2022-05-24 2023-12-01 浙江兆隆智能装备有限公司 Frame assembly, second frame, third frame, computerized embroidery machine and method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017288A1 (en) * 1996-10-22 1998-04-30 Scotia Holdings Plc Lithium containing medicament for combatting papilloma virus infections
US20050075276A1 (en) * 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386072A (en) 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
AU2819397A (en) 1996-05-07 1997-11-26 Presidents And Fellows Of Harvard College Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
WO2001078751A1 (en) * 2000-04-17 2001-10-25 'armenicum+' Jsc Antiviral and antibacterial pharmaceutical preparation 'armenicum' and its use for treatment of infectious diseases
WO2005086814A2 (en) * 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017288A1 (en) * 1996-10-22 1998-04-30 Scotia Holdings Plc Lithium containing medicament for combatting papilloma virus infections
US20050075276A1 (en) * 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses

Also Published As

Publication number Publication date
US8048454B2 (en) 2011-11-01
US20120309807A1 (en) 2012-12-06
WO2005086814A2 (en) 2005-09-22
US20080175923A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2006044825A3 (en) Mitotic kinesin inhibitors and methods of use thereof
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005086814A3 (en) Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2004094388A3 (en) Indazole derivatives as jnk inhibitors
WO2008054200A3 (en) Use of nutritional compositions for preventing disorders
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
MXPA05013824A (en) 5-membered heterocycle-based p38 kinase inhibitors.
MX2009006339A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity.
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
TW200612951A (en) New pyridazin-3(2h)-one derivatives
WO2007142755A3 (en) Purine analogs
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006106311A3 (en) Combination treatment methods for treating sex-hormone dependent disease and fertility treatment
WO2006130679A3 (en) Composition and method for the treatment of allergic rhinitis
WO2006021000A3 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
WO2008023003A8 (en) Drug combinations for treating airway diseases
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2006069808A3 (en) Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10598671

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase